<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> Announces $50 Million Private Placement to Advance Sanfilippo Syndrome Therapy
Spruce Biosciences Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced a private placement financing expected to raise approximately $50 million in gross proceeds. The funds will support the advancement of tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), with plans for a biologics license application submission in early 2026 and a potential U.S. commercial launch later that year. Under the terms of the agreement, investors will purchase around 502,181 shares of Spruce Biosciences' common stock at $68.00 per share. Certain investors will also acquire pre-funded warrants to purchase up to 233,144 shares of common stock at $67.99 per warrant, with an exercise period of five years. Leerink Partners, Citizens Capital Markets, and H.C. Wainwright & Co. are serving as placement agents, and Oppenheimer & Co. is acting as capital markets advisor for the transaction. The private placement is expected to close around October 9, 2025, subject to customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251008435141) on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.